Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: LV5FU2
Drug: Capecitabine
Drug: Streptozocin
Drug: Temozolomide
Drug: Bevacizumab

First Posted Date: 2017-11-22

Last Posted Date: 2024-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 140

Registration Number: NCT03351296

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
CHU de Caen, Caen, Calvados, France
🇫🇷
ICM Val d'Aurelle, Montpellier, Hérault, France

and more 16 locations

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Castrate-resistant Prostate (CRPC) Cancer

Interventions: Drug: ODM-201
Drug: Enzalutamide

First Posted Date: 2017-10-19

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 250

Registration Number: NCT03314324

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

Phase 2

Recruiting

Conditions: Head and Neck Mucosal Melanomas

Interventions: Drug: Pembrolizumab
Procedure: Surgery
Radiation: IMRT
Drug: Lenvatinib

First Posted Date: 2017-10-18

Last Posted Date: 2024-05-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 60

Registration Number: NCT03313206

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

Phase 1

Conditions: Gynecologic Cancer

Interventions: Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
Radiation: External beam radiotherapy (EBRT)
Radiation: Uterovaginal brachytherapy
Drug: Chemotherapy (cisplatin)

First Posted Date: 2017-10-12

Last Posted Date: 2021-07-07

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 18

Registration Number: NCT03308604

Locations: 🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Phase 2

Conditions: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Interventions: Drug: Trametinib
Drug: Dabrafenib
Radiation: 131I
Drug: rhTSH

First Posted Date: 2017-08-10

Last Posted Date: 2021-09-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 40

Registration Number: NCT03244956

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Lung Cancer
Oesophageal Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Radiation: SBRT

First Posted Date: 2017-07-11

Last Posted Date: 2024-03-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 54

Registration Number: NCT03212469

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-07-11

Last Posted Date: 2023-01-20

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 41

Registration Number: NCT03212651

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

Phase 2

Terminated

Conditions: Very High Risk Neuroblastoma

Interventions: Radiation: mIBG
Drug: Thiotepa
Drug: Topotecan
Procedure: Autologous stem cell transplant

First Posted Date: 2017-05-24

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT03165292

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹
St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹
Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy

and more 6 locations

Optimized Angiomammography and Comparison With Standard Angiomammography

Conditions: Patients for Whom an Angiomammogram Examination is Requested Whether Its Indication

Interventions: Other: Angiommamography

First Posted Date: 2017-05-16

Last Posted Date: 2017-07-11

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 100

Registration Number: NCT03155386

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot

Phase 2

Conditions: Head and Neck Cancer

Interventions: Procedure: Detection and resection of sentinel lymph node

First Posted Date: 2017-01-05

Last Posted Date: 2017-01-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 100

Registration Number: NCT03010553

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy